KIT and acute myeloid leukemia: Given the prognostic implication of the gain-of-function KIT mutations, and over-expression of KIT observed in most CBF-AML including those with KIT mutations (48), studies have explored the addition of KIT inhibitors such as dasatinib and avapritinib to frontline therapy (49) to improve the outcome.